We are delighted to announce the official launch of IMPACT-CRC, an innovative European research project funded by the European Partnership for Personalised Medicine (EP PerMed). The project is focused on improving treatment strategies for people living with colorectal cancer (CRC).

While immunotherapy has brought new hope for some patients with CRC, it does not work for everyone. IMPACT-CRC aims to understand why patients respond differently and to ensure that the right treatment reaches the right patient at the right time.

This project will study tumour and blood samples using advanced technologies and artificial intelligence to identify biomarkers, which are measurable biological signals in the body that can help doctors predict which treatments are most likely to be effective for each patient.

The project involves leading European institutions from Belgium (KU Leuven), Germany (TU Dresden and Georg-Speyer-Haus), Italy (Fondazione IRCCS Istituto Nazionale dei Tumori), Spain (CNAG and VHIO), and DiCE as the European patient organisation, ensuring that patients and the public are informed, engaged, and empowered throughout the project. Together, these partners will work closely to make CRC treatment more personalised and effective.  

By putting patients at the centre, IMPACT-CRC aims to support better treatment decisions, reduce unnecessary side effects, and improve outcomes for people living with colorectal cancer.

Learn more about the project here.

Author:

Juliana Calheiros